Gail brings more than 25 years of pharmaceutical development and regulatory experience including rare diseases with both large and small pharmaceutical companies. She was most recently the chief executive officer of ProMIS, a biotechnology company focused on the discovery and development of antibody therapeutics targeting misfolded proteins such as toxic oligomers, implicated in the development of neurodegenerative diseases. Prior positions included executive vice president and global chief development officer at Zogenix, Inc., a rare disease company; chief clinical and regulatory officer of Marinus Pharmaceuticals, with a focus on adult and pediatric neuropsychiatric disorders; and vice president, therapeutic area head for neuroscience clinical development and medical affairs at Novartis Pharmaceuticals Corporation.

Gail began her career in pharmaceutical drug development at Pfizer Inc., where she worked in clinical development and global medical affairs, directing programs through all stages of clinical development and regulatory submissions.

She has authored more than 50 scientific articles in the areas of neuropsychopharmacology and drug effects. Gail currently serves on the board of directors of DURECT Corporation (Nasdaq: DRRX) and is a director on the Board of the American Society for Experimental Neurotherapeutics. She holds a PhD in neuropsychopharmacology from the University of Chicago, where she received the Ginsburg Prize for Dissertation Excellence and is a director on the Medical and Biological Sciences Alumni Board. Gail also holds a BA in biochemistry from the University of Virginia.